Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (2): 144-150.doi: 10.6040/j.issn.1673-3770.0.2020.484

Previous Articles     Next Articles

Research progress in the inflammatory reaction and anti-inflammatory treatments in dry eye

DI Yu,LI Ying   

  1. Department of Ophthalmology, Chinese Academy of Medical Sciences / Peking Union Medical College / Peking Union Medical College Hospital, Beijing 100730, China
  • Published:2022-04-15

PDF (PC)

1250

Abstract: Dry eye is a multifactorial disease of the tear film and ocular surface. In recent years, it has become one of the most common ocular surface diseases, with its prevalence increasing every year. Inflammation plays a key role in the pathogenesis of dry eye. It can stimulate ocular surface cells, activate the local immune response, lead to unstable tear films, increase the osmolality of tears, and then cause local ocular surface damage. Multiple inflammatory mediators and immune cells participate in the development of dry eye. There is increasing research on the inflammatory reaction involved in dry eye, and this paper reviews the inflammatory mediators, immune cells, immune response, and anti-inflammatory treatments to systematically understand the inflammatory reaction mechanism of dry eye and its clinical significance.

Key words: Dry eye, Inflammatory mediator, Inflammatory reaction, Anti-inflammation, Treatment

CLC Number: 

  • R777.34
[1] Periman LM, Perez VL, Saban DR, et al. The immunological basis of dry eye disease and current topical treatment options[J]. J Ocul Pharmacol Ther, 2020, 36(3): 137-146. doi:10.1089/jop.2019.0060.
[2] Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report[J]. Ocul Surf, 2017, 15(3): 276-283. doi:10.1016/j.jtos.2017.05.008.
[3] Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease[J]. Int Rev Immunol, 2013, 32(1): 19-41. doi:10.3109/08830185.2012.748052.
[4] 孙子雯, 崔洪玮, 孙喜灵, 等. 干眼病的病因、发病机制及治疗进展[J]. 山东大学耳鼻喉眼学报, 2019, 3(33):159-166. doi: 10.6040/j.issn.1673-3770.0.2018.411. SUN Ziwen, CUI Hongwei, SUN Xiling, et al. Etiology, pathogenesis, and management of dry eye[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 3(33):159-166. doi: 10.6040/j.issn.1673-3770.0.2018.411.
[5] Yagci A, Gurdal C. The role and treatment of inflammation in dry eye disease[J]. Int Ophthalmol, 2014, 34(6): 1291-1301. doi:10.1007/s10792-014-9969-x.
[6] 高雅, 李冰, 陈研遐, 等. 白介素1β在干眼患者眼表的表达[J]. 中华眼视光学与视觉科学杂志, 2014, 16(4): 228-232. doi: 10.3760/cma.j.issn.1674-845X.2014.04.009. GAO Ya, LI Bing, CHEN Yanxia, et al. A study of the expression of IL-1 beta on the ocular surface in dry eye patients[J]. Chinese Journal of Optometry & Ophthalmology, 2014, 16(4): 228-232. doi: 10.3760/cma.j.issn.1674-845X.2014.04.009.
[7] Benitez J, Cantu-Dibildox J, Sanz-González SM, et al. Cytokine expression in tears of patients with Glaucoma or dry eye disease: a prospective, observational cohort study[J]. Eur J Ophthalmol, 2019, 29(4): 437-443. doi:10.1177/1120672118795399.
[8] Landsend ECS, Utheim A, Pedersen HR, et al. The level of inflammatory tear cytokines is elevated in congenital aniridia and associated with meibomian gland dysfunction[J]. Invest Ophthalmol Vis Sci, 2018, 59(5): 2197-2204. doi:10.1167/iovs.18-24027.
[9] Lee H, Chung B, Kim KS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial[J]. Am J Ophthalmol, 2014, 158(6): 1172-1183.e1. doi:10.1016/j.ajo.2014.08.015.
[10] Bi Y, Yang R. Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions[J]. Scand J Immunol, 2012, 75(6): 543-552. doi:10.1111/j.1365-3083.2012.02686.x.
[11] Higuchi A, Kawakita T, Tsubota K. IL-6 induction in desiccated corneal epithelium in vitro and in vivo[J]. Mol Vis, 2011, 17: 2400-2406. doi: 10.2214/ajr.142.6.1205.
[12] Na KS, Mok JW, Kim JY, et al. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease[J]. Invest Ophthalmol Vis Sci, 2012, 53(9): 5443-5450. doi:10.1167/iovs.11-9417.
[13] McDonnell PJ, Pflugfelder SC, Stern ME, et al. Study design and baseline findings from the progression of ocular findings(PROOF)natural history study of dry eye[J]. BMC Ophthalmol, 2017, 17(1): 265. doi:10.1186/s12886-017-0646-5.
[14] Jung JW, Han SJ, Nam SM, et al. Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status[J]. Clin Exp Ophthalmol, 2016, 44(7): 555-562. doi:10.1111/ceo.12744.
[15] De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress[J]. Mucosal Immunol, 2009, 2(3): 243-253. doi:10.1038/mi.2009.5.
[16] Chen Y, Chauhan SK, Lee HS, et al. Chronic dry eye disease is principally mediated by effector memory Th17 cells[J]. Mucosal Immunol, 2014, 7(1): 38-45. doi:10.1038/mi.2013.20.
[17] Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in sjögren syndrome dry eye patients and non-sjögren syndrome dry eye patients[J]. Am J Ophthalmol, 2013, 156(2): 247-253. doi:10.1016/j.ajo.2013.04.003.
[18] Mrugacz M, Ostrowska L, Bryl A, et al. Pro-inflammatory cytokines associated with clinical severity of dry eye disease of patients with depression[J]. Adv Med Sci, 2017, 62(2): 338-344. doi:10.1016/j.advms.2017.03.003.
[19] Tong L, Beuerman R, Simonyi S, et al. Effects of punctal occlusion on clinical signs and symptoms and on tear cytokine levels in patients with dry eye[J]. Ocul Surf, 2016, 14(2): 233-241. doi:10.1016/j.jtos.2015.12.004.
[20] Pflugfelder SC, De Paiva CS, Moore QL, et al. Aqueous tear deficiency increases conjunctival interferon-γ(IFN-γ)expression and goblet cell loss[J]. Invest Ophthalmol Vis Sci, 2015, 56(12): 7545-7550. doi:10.1167/iovs.15-17627.
[21] Jackson DC, Zeng W, Wong CY, et al. Tear interferon-gamma as a biomarker for evaporative dry eye disease[J]. Invest Ophthalmol Vis Sci, 2016, 57(11): 4824-4830. doi:10.1167/iovs.16-19757.
[22] Chotikavanich S, de Paiva CS, Li DQ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome[J]. Invest Ophthalmol Vis Sci, 2009, 50(7): 3203-3209. doi:10.1167/iovs.08-2476.
[23] Yang S, Lee HJ, Kim DY, et al. The use of conjunctival staining to measure ocular surface inflammation in patients with dry eye[J]. Cornea, 2019, 38(6): 698-705. doi:10.1097/ico.0000000000001916.
[24] Messmer EM, von Lindenfels V, Garbe A, et al. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay[J]. Ophthalmology, 2016, 123(11): 2300-2308. doi:10.1016/j.ophtha.2016.07.028.
[25] Schargus M, Ivanova S, Kakkassery V, et al. Correlation of tear film osmolarity and 2 different MMP-9 tests with common dry eye tests in a cohort of non-dry eye patients[J]. Cornea, 2015, 34(7): 739-744. doi:10.1097/ico.0000000000000449.
[26] Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease[J]. Mol Vis, 2010, 16: 862-873. PMID: 20508732.
[27] Massingale ML, Li XH, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients[J]. Cornea, 2009, 28(9): 1023-1027. doi:10.1097/ico.0b013e3181a16578.
[28] Choi W, Li ZR, Oh HJ, et al. Expression of CCR5 and its ligands CCL3, -4, and -5 in the tear film and ocular surface of patients with dry eye disease[J]. Curr Eye Res, 2012, 37(1): 12-17. doi:10.3109/02713683.2011.622852.
[29] Nicolle P, Liang H, Reboussin E, et al. Proinflammatory markers, chemokines, and enkephalin in patients suffering from dry eye disease[J]. Int J Mol Sci, 2018, 19(4): 1221. doi:10.3390/ijms19041221.
[30] Wang T, Li WH, Cheng HH, et al. The important role of the chemokine axis CCR7-CCL19 and CCR7-CCL21 in the pathophysiology of the immuno-inflammatory response in dry eye disease[J]. Ocular Immunol Inflamm, 2019: 1-12. doi:10.1080/09273948.2019.1674891.
[31] Lefort CT, Ley K. Neutrophil arrest by LFA-1 activation[J]. Front Immunol, 2012, 3: 157. doi:10.3389/fimmu.2012.00157.
[32] Hogg N, Laschinger M, Giles K, et al. T-cell integrins: more than just sticking points[J]. J Cell Sci, 2003, 116(Pt 23): 4695-4705. doi:10.1242/jcs.00876.
[33] Liu M, Gao H, Wang T, et al. An essential role for dendritic cells in vernal keratoconjunctivitis: analysis by laser scanning confocal microscopy[J]. Clin Exp Allergy, 2014, 44(3): 362-370. doi:10.1111/cea.12264.
[34] Hamrah P, Huq SO, Liu Y, et al. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells[J]. J Leukoc Biol, 2003, 74(2): 172-178. doi:10.1189/jlb.1102544.
[35] El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease[J]. Invest Ophthalmol Vis Sci, 2009, 50(8): 3802-3807. doi:10.1167/iovs.08-2417.
[36] De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous Metaplasia is modulated by interferon-gamma[J]. Invest Ophthalmol Vis Sci, 2007, 48(6): 2553-2560. doi:10.1167/iovs.07-0069.
[37] Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression[J]. J Immunol, 2009, 182(3): 1247-1252. doi:10.4049/jimmunol.182.3.1247.
[38] von Knethen A, Heinicke U, Weigert A, et al. Histone deacetylation inhibitors as modulators of regulatory T cells[J]. Int J Mol Sci, 2020, 21(7): 2356. doi:10.3390/ijms21072356.
[39] Ratay ML, Balmert SC, Bassin EJ, et al. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease[J]. Acta Biomater, 2018, 71: 261-270. doi:10.1016/j.actbio.2018.03.002.
[40] 蔡丽萍, 张宏. 炎症免疫相关信号通路在干眼发病机制中的研究进展[J]. 国际眼科杂志, 2016, 16(6): 1084-1088. doi:10.3980/j.issn.1672-5123.2016.6.20. LIPING Cai, HONG Zhang. Research progress on inflammatory immunity related signaling pathway for the pathogenesis of dry eye[J]. Int Eye Sci, 2016, 16(6): 1084-1088. doi:10.3980/j.issn.1672-5123.2016.6.20.
[41] Hattori T, Takahashi H, Dana R. Novel insights into the immunoregulatory function and localization of dendritic cells[J]. Cornea, 2016, 35(Suppl 1): S49-S54. doi:10.1097/ico.0000000000001005.
[42] Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease[J]. Exp Eye Res, 2013, 117: 118-125. doi:10.1016/j.exer.2013.08.013.
[43] Pflugfelder SC, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop(2007)[C] //2007, 5: 163-178.
[44] Pinto-Fraga J, Lopez-Miguel A, Gonzalez-Garcia MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial[J]. Ophthalmology, 2016, 123(1):141-53. doi: 10.1016/j.ophtha.2015.09.029.
[45] Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with sjögren's syndrome[J]. Chonnam Med J, 2015, 51(1): 26-32. doi:10.4068/cmj.2015.51.1.26.
[46] Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease[J]. Ophthalmology, 2000, 107(4): 631-639. doi:10.1016/S0161-6420(99)00176-1.
[47] Ji YW, Kim HM, Ryu SY, et al. Changes in human tear proteome following topical treatment of dry eye disease: cyclosporine A versus diquafosol tetrasodium[J]. Invest Ophthalmol Vis Sci, 2019, 60(15): 5035-5044. doi:10.1167/iovs.19-27872.
[48] Daull P, Barabino S, Feraille L, et al. Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops[J]. Curr Eye Res, 2019, 44(5): 476-485. doi:10.1080/02713683.2018.1563197.
[49] Guimaraes de Souza R, Yu Z, Stern ME, et al. Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast[J]. J Ocul Pharmacol Ther, 2018, 34(7): 543-549. doi:10.1089/jop.2018.0047.
[50] Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease[J]. Ther Adv Ophthalmol, 2019, 11: 2515841419870366. doi:10.1177/2515841419870366.
[51] Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist(SAR 1118)for the treatment of dry eye[J]. Am J Ophthalmol, 2012, 153(6): 1050-1060.e1. doi:10.1016/j.ajo.2011.11.003.
[52] Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase Ⅲ, randomized, double-masked, placebo-controlled trial(OPUS-3)[J]. Ophthalmology, 2017, 124(1): 53-60. doi:10.1016/j.ophtha.2016.09.025.
[53] Kim CE, Kleinman HK, Sosne G, et al. RGN-259(thymosin β4)improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model[J]. Sci Rep, 2018, 8(1): 1-14. doi:10.1038/s41598-018-28861-5.
[54] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial[J]. Cornea, 2015, 34(5): 491-496. doi:10.1097/ico.0000000000000379.
[1] LI Kai, LUO Dan. Runmu ling formula ameliorates ocular surface damage in dry eye rats by activating the LC3-ATG5 autophagy pathway and inhibiting inflammatory factor expression [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(3): 92-101.
[2] YANG Guanying, LI Yuanbin. Advances in the application of artificial intelligence to dry eye disease management [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(3): 115-120.
[3] FANG Lu, LEI Yudan, WANG Hua. Meta-analysis of clinical effect of cyclosporine eye drops in combination with sodium hyaluronate eye drops in the treatment of dry eye syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 65-73.
[4] NING Yuyun, LI Tong, ZHANG Xinxin. Topical pharmacologic treatment of dry eye disease associated with meibomian gland dysfunction [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 125-132.
[5] ZHU Mingqiong, LI Zheng, LIU Ru, TIAN Tao, PENG Jingli, LYU Qianyi, TAN Huaxia. The application of AI screening system based on OCT/OCTA in the evaluation of the effect of anti VEGF treatment in patients with diabetes macular edema [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 68-73.
[6] LU Zhaoyang, ZHAI Zhaoxue, WANG Huikang, SHAO Liting, ZHANG Yu. COVID-19 treatment-induced diabetic ketoacidosis combined with rhino-orbital cerebral mucormycosis: a case report and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 90-94.
[7] LIU Yijie, LU Xiuzhen, WU Qiuxin. Research rogress of exosomes in the pathogenesis, diagnosis and treatment in ophthalmic diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 135-141.
[8] LI Yuchen, WANG Xu. The efficacy and safety of scleral lenses in treating severe ocular surface disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 149-154.
[9] LI Zan, LU Qi, SHEN Weidong, HOU Zhaohui, WU Nan. Clinical diagnosis and treatment features of 18 cases of necrotizing otitis externa [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 17-22.
[10] LIU Yuzhu, CHEN Yao, YUAN Tiejun, LI Chunsen, LI Bo. Larynx fibrosarcoma: a case report and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 133-137.
[11] GU Zhanxin, ZHAO Zhouyang, ZHANG Xiaobin, YANG Yimei, HUANG Lijin, HUANG Yan. Syndrome differentiation treatment and understanding of traditional Chinese medicine in carotid blowout syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 100-107.
[12] SHI Jinlian, LI Jianxing, HUANG Yousheng, LIN Mingxuan, LIU Lingyun, LU Yongtian. Research status and progress in diagnosis and treatment of laryngeal inflammatory myofibroblastic tumor [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 186-192.
[13] WU Wei, WANG Lei, CHEN Sheng, LI Lianyong, WANG Gang. Multidisciplinary research and advances in gastro-oesophageal reflux disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(6): 1-14.
[14] LIU Lianlian, LI Jinrang. Obstructive sleep apnea and laryngopharyngeal reflux [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(6): 15-22.
[15] ZHU Lang, LIU Zhiqi. Utilization of real-world data from mobile health applications in therapeutic interventions for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 135-139.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd